News & analysis on the clinical development and manufacture of large molecule drugs
Gryos and Cygnus release first in a planned range of ready-to-use bioprocess impurity reagent sets
By Jane Byrne
- Last updated on
Gyros Protein Technologies and Cygnus Technologies are introducing a new immunoassay solution: the reagent detects host cell impurities from HEK 293 cells used in vaccine and viral vector manufacturing for cell and gene therapies.
The move is part of the next phase of the two companies’ on-going collaboration: the HEK 293 HCP Assay Reagent Set for Gyrolabis the first of a planned range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform.
The partners said the new automated nanoliter-scale immunoassay solution supports fast development and streamlined process transfer, increasing productivity, providing speedier results with less hands-on time, and reduced sample volume and reagent consumption. It also enables researchers to generate more data in less time for a broader range of analytical applications, allowing faster decision-making, said the collaborators.
Mark Vossenaar, vice president, general manager, biopharmaceutical development division, Mesa Labs, Gyros’ parent group, said. “There is a real need for analytical tools that support fast turn-around time and small sample volume, to accelerate viral vector bioprocess workflows and reduce time to market. HEK 293 HCP Assay Reagent Set for Gyrolab is the first of this new, high quality range, and we hope to announce further releases in the near future.”